CO4960666A1 - Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion - Google Patents
Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacionInfo
- Publication number
- CO4960666A1 CO4960666A1 CO98045455A CO98045455A CO4960666A1 CO 4960666 A1 CO4960666 A1 CO 4960666A1 CO 98045455 A CO98045455 A CO 98045455A CO 98045455 A CO98045455 A CO 98045455A CO 4960666 A1 CO4960666 A1 CO 4960666A1
- Authority
- CO
- Colombia
- Prior art keywords
- thiophene
- methylene
- butyl
- imidazol
- methyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 title 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 title 1
- 229960004563 eprosartan Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000006386 neutralization reaction Methods 0.000 title 1
- -1 4- carboxy-phenyl Chemical group 0.000 abstract 2
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- OJRJAEIZNDZTIP-UHFFFAOYSA-N 2-(thiophen-2-ylmethyl)prop-2-enoic acid Chemical compound OC(=O)C(=C)CC1=CC=CS1 OJRJAEIZNDZTIP-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 230000005591 charge neutralization Effects 0.000 abstract 1
- 239000008139 complexing agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5499097P | 1997-08-06 | 1997-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4960666A1 true CO4960666A1 (es) | 2000-09-25 |
Family
ID=21994861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98045455A CO4960666A1 (es) | 1997-08-06 | 1998-08-10 | Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1027047B1 (https=) |
| JP (1) | JP4463975B2 (https=) |
| KR (1) | KR100508044B1 (https=) |
| CN (1) | CN1276724A (https=) |
| AR (1) | AR015930A1 (https=) |
| AT (1) | ATE341325T1 (https=) |
| AU (1) | AU739295B2 (https=) |
| BR (1) | BR9811926A (https=) |
| CA (1) | CA2299470C (https=) |
| CO (1) | CO4960666A1 (https=) |
| CY (1) | CY1105851T1 (https=) |
| CZ (1) | CZ296274B6 (https=) |
| DE (1) | DE69836095T2 (https=) |
| DK (1) | DK1027047T3 (https=) |
| ES (1) | ES2273433T3 (https=) |
| HU (1) | HUP0201624A3 (https=) |
| IL (1) | IL134378A (https=) |
| NO (1) | NO317771B1 (https=) |
| NZ (1) | NZ502644A (https=) |
| PL (1) | PL198875B1 (https=) |
| PT (1) | PT1027047E (https=) |
| SA (1) | SA98190592B1 (https=) |
| TR (1) | TR200000350T2 (https=) |
| TW (1) | TW570921B (https=) |
| WO (1) | WO1999007365A1 (https=) |
| ZA (1) | ZA987018B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA991922B (en) * | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
| ATE289204T1 (de) * | 1999-04-28 | 2005-03-15 | Takeda Pharmaceutical | Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie |
| KR20120058618A (ko) | 2003-01-31 | 2012-06-07 | 다이이찌 산쿄 가부시키가이샤 | 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약 |
| NO323391B1 (no) | 2005-09-28 | 2007-04-23 | Hts Hans Torgersen & Sonn As | Barnepose |
| US20100278909A1 (en) * | 2007-06-06 | 2010-11-04 | Dexcel Ltd. | Process for forming solid oral dosage forms of angiotensin ii receptor antagonists |
| JP5476782B2 (ja) * | 2009-04-21 | 2014-04-23 | 大正製薬株式会社 | アルギニン含有錠剤の製造方法 |
| JP5446716B2 (ja) * | 2009-10-21 | 2014-03-19 | 大正製薬株式会社 | アルギニン及びカルニチン含有錠剤の製造方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
| NZ239161A (en) * | 1990-07-31 | 1994-01-26 | Smithkline Beecham Corp | Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments, |
| KR100222252B1 (ko) * | 1990-12-14 | 1999-10-01 | 스튜어트 알. 수터 | 안지오텐신 ii 수용체 차단 조성물 |
| JP3214856B2 (ja) * | 1990-12-14 | 2001-10-02 | スミスクライン・ビーチャム・コーポレイション | イミダゾリル−アルケン酸 |
| US5187159A (en) * | 1991-10-07 | 1993-02-16 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole |
| DE4208052A1 (de) * | 1992-03-13 | 1993-09-16 | Bayer Ag | Imidazolyl substituierte phenylessigsaeureamide |
| FR2688781B1 (fr) * | 1992-03-23 | 1994-07-01 | Sanofi Elf | Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
| DE4210787A1 (de) * | 1992-04-01 | 1993-10-07 | Bayer Ag | Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate |
| JPH0841053A (ja) * | 1994-07-28 | 1996-02-13 | Nkk Corp | ヘテロアリールアルキル基を有するピリミジン誘導体及 び該誘導体を有効成分として含有するアンジオテンシン ｉｉ拮抗剤 |
| US5645839A (en) * | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| JP3092946B2 (ja) * | 1995-12-14 | 2000-09-25 | メルク エンド カンパニー インコーポレーテッド | ゴナドトロピン放出ホルモン拮抗剤 |
-
1998
- 1998-08-04 DK DK98939213T patent/DK1027047T3/da active
- 1998-08-04 CZ CZ20000406A patent/CZ296274B6/cs not_active IP Right Cessation
- 1998-08-04 EP EP98939213A patent/EP1027047B1/en not_active Expired - Lifetime
- 1998-08-04 TR TR2000/00350T patent/TR200000350T2/xx unknown
- 1998-08-04 BR BR9811926-5A patent/BR9811926A/pt not_active Application Discontinuation
- 1998-08-04 KR KR10-2000-7001173A patent/KR100508044B1/ko not_active Expired - Fee Related
- 1998-08-04 JP JP2000506956A patent/JP4463975B2/ja not_active Expired - Fee Related
- 1998-08-04 IL IL13437898A patent/IL134378A/en not_active IP Right Cessation
- 1998-08-04 DE DE69836095T patent/DE69836095T2/de not_active Expired - Lifetime
- 1998-08-04 AU AU87688/98A patent/AU739295B2/en not_active Ceased
- 1998-08-04 ES ES98939213T patent/ES2273433T3/es not_active Expired - Lifetime
- 1998-08-04 PT PT98939213T patent/PT1027047E/pt unknown
- 1998-08-04 WO PCT/US1998/016245 patent/WO1999007365A1/en not_active Ceased
- 1998-08-04 PL PL341562A patent/PL198875B1/pl not_active IP Right Cessation
- 1998-08-04 NZ NZ502644A patent/NZ502644A/en unknown
- 1998-08-04 HU HU0201624A patent/HUP0201624A3/hu unknown
- 1998-08-04 CA CA2299470A patent/CA2299470C/en not_active Expired - Fee Related
- 1998-08-04 CN CN98809802A patent/CN1276724A/zh active Pending
- 1998-08-04 AT AT98939213T patent/ATE341325T1/de active
- 1998-08-05 ZA ZA987018A patent/ZA987018B/xx unknown
- 1998-08-05 AR ARP980103871A patent/AR015930A1/es active IP Right Grant
- 1998-08-10 CO CO98045455A patent/CO4960666A1/es unknown
- 1998-08-26 TW TW087112928A patent/TW570921B/zh not_active IP Right Cessation
- 1998-09-27 SA SA98190592A patent/SA98190592B1/ar unknown
-
2000
- 2000-02-04 NO NO20000577A patent/NO317771B1/no not_active IP Right Cessation
-
2006
- 2006-12-13 CY CY20061101797T patent/CY1105851T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9810487A (pt) | Processo para a produção de um produto detergente granular. | |
| DE69807104D1 (de) | Formulierungen mit gesteuerter freisetzung | |
| ES2171471T3 (es) | Sistema para la administracion oral de desferrioxamina. | |
| NO985938L (no) | Anordning for topikal behandling av akne og fremgangsmÕte ved fremstilling derav | |
| TR200103178T2 (tr) | İntegrinlerin reseptörlere bağlanmasını engelleyen karboksilik asit türevleri. | |
| BR0013720A (pt) | Formulação em pelota de liberação controlada | |
| IL111647A0 (en) | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them | |
| BR9906903A (pt) | Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto | |
| ES8504110A1 (es) | "procedimiento para preparar nonapeptidos y decapeptidos analogos a lhrh" | |
| NO175240C (no) | Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler | |
| IS2354B (is) | Lyfjasamsetning sem mögulegt er að hleypa | |
| MY148594A (en) | Stable, durable granules with active agents | |
| BR0009759A (pt) | Formulação agroquìmica na forma sólida granular, e, métodos para preparação de uma mistura de pulverização e para tratamento de plantas | |
| CO4960666A1 (es) | Complejo de neutralizacion de cargas con arginilo de epro- sartan y un procedimiento para su produccion y formulacion | |
| BR9609411A (pt) | Peptìdeo, composição, vacina, e, processos para inocular um animal com a vacina, afetar uma ou mais caracterìsticas reprodutivas ou comportamentais de um animal e imunocastrar um porco. | |
| BR9810711A (pt) | Formulação tópica de pulverização antipruriginosa, e, processo para prevenção ou tratamento de prurido em um paciente | |
| BR0013283A (pt) | Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo | |
| BR9909121A (pt) | Composto, composição farmacêutica, e, processos para inibir a liberação de hormÈnio de luteinização (lh) em um mamìfero em necessidade de tal tratamento e para preparar um composto | |
| BR9909080A (pt) | Composto, composição farmacêutica para inibir a liberação de lh, processo de inibir a liberação de lh em um mamìfero em necessidade de tal tratamento, processo para preparar um composto | |
| BR0012939A (pt) | Tablete de uma composição particulada compactada, e, processos para produzir grânulos, e para produzir um tablete | |
| BE899277A (fr) | Agents antimycotiques a haute liberation de substance active sous forme d'une solution et d'une pulverisation. | |
| MX9304776A (es) | Nuevo proceso diseñado para la alquilacion de pro uctos aromaticos. | |
| JPS54126722A (en) | Slow release antibiotic tablet | |
| JPS5282715A (en) | Long acting drug composition | |
| Atkins et al. | Rat osteogenic sarcoma cells: modulation of hormone stimulated cyclic AMP production by prostaglandin antagonists and biosynthesis inhibitors |